Adicet Bio Inc (ACET) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adicet Bio Inc (ACET) has a cash flow conversion efficiency ratio of -0.165x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.82 Million) by net assets ($120.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ACET market cap for the company's overall valuation and market capitalisation.
Adicet Bio Inc - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Adicet Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Adicet Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adicet Bio Inc ranked by their cash flow conversion efficiency. Explore ACET cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Peace Acquisition Corp Ordinary Shares
NASDAQ:PECE
|
-0.003x |
|
Kothari Petrochemicals Limited
NSE:KOTHARIPET
|
0.130x |
|
MaxCyte Inc
NASDAQ:MXCT
|
-0.041x |
|
Casino Guichard Perrachon SA
PA:CO
|
0.071x |
|
Tongyang
KO:001520
|
0.020x |
|
C&G Hi Tech Co.Ltd
KQ:264660
|
0.021x |
|
Panache Digilife Limited
NSE:PANACHE
|
0.050x |
|
TIAN GE INT.HLDGS DL-0001
F:04T
|
N/A |
Annual Cash Flow Conversion Efficiency for Adicet Bio Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of Adicet Bio Inc from 2008 to 2025. View latest Adicet Bio Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $159.21 Million | $-95.25 Million | -0.598x | -20.85% |
| 2024-12-31 | $186.61 Million | $-92.38 Million | -0.495x | +10.11% |
| 2023-12-31 | $170.18 Million | $-93.72 Million | -0.551x | -259.64% |
| 2022-12-31 | $292.34 Million | $-44.77 Million | -0.153x | +9.08% |
| 2021-12-31 | $303.13 Million | $-51.05 Million | -0.168x | +55.49% |
| 2020-12-31 | $109.83 Million | $-41.55 Million | -0.378x | -181.91% |
| 2019-12-31 | $-60.37 Million | $-27.88 Million | 0.462x | +364.74% |
| 2018-12-31 | $104.20 Million | $-18.18 Million | -0.174x | +24.96% |
| 2017-12-31 | $49.69 Million | $-11.55 Million | -0.232x | -948.40% |
| 2016-12-31 | $304.44 Million | $8.34 Million | 0.027x | -72.20% |
| 2015-12-31 | $254.21 Million | $25.06 Million | 0.099x | -9.63% |
| 2014-12-31 | $233.58 Million | $25.48 Million | 0.109x | -10.55% |
| 2013-12-31 | $194.64 Million | $23.73 Million | 0.122x | +54.37% |
| 2012-12-31 | $168.00 Million | $13.27 Million | 0.079x | -18.90% |
| 2011-12-31 | $144.15 Million | $14.04 Million | 0.097x | +178.13% |
| 2010-12-31 | $124.35 Million | $-15.50 Million | -0.125x | -169.42% |
| 2009-12-31 | $125.38 Million | $22.51 Million | 0.180x | +44.01% |
| 2008-12-31 | $123.67 Million | $15.42 Million | 0.125x | -- |
About Adicet Bio Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops … Read more